Clinical Trials on Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma

Total 823 results

Health Pharma Professional Research

Withdrawn

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma, Advanced | Malignant Pleural Mesothelioma, Unresectable

Mexico
National Cancer Institute (NCI)

Active, not recruiting

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Unresectable Solid Neoplasm | Advanced Pleural Malignant Mesothelioma | Advanced Peritoneal Malignant Mesothelioma

United States
RS Oncology LLC

Recruiting

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Effusion, Malignant | Mesotheliomas Pleural | Malignant Pleural Effusion | Mesothelioma; Lung

United Kingdom
Incyte Corporation

Withdrawn

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Advanced and/or Metastatic Solid Tumors | Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer | Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
National Cancer Institute (NCI)

Withdrawn

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Malignant Pleural Mesotheliomas (Mpm) | Malignant Pleural Effusions (Mpe) | Epithelial Tumors, Malignant | Pleural Effusions, Malignant | Mesothelin (Msln)

United States
Ain Shams University

Completed

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM) (VITMPM)

Malignant Pleural Mesotheliomas

Egypt
Eli Lilly and Company

Completed

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Malignant Pleural Mesotherioma

Japan
NRG Oncology
National Cancer Institute (NCI)

Terminated

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Stage I Pleural Malignant Mesothelioma AJCC v8 | Stage IA Pleural Malignant Mesothelioma AJCC v8 | Stage IB Pleural Malignant Mesothelioma AJCC v8 | Stage II Pleural Malignant Mesothelioma AJCC v8 | Stage IIIA Pleural Malignant...

United States, Canada
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma (MESO-PRIME)

Advanced Malignant Pleural Mesothelioma

United Kingdom
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant Neoplasm

United States
Swiss Group for Clinical Cancer Research

Completed

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Malignant Pleural Mesothelioma, Advanced

Switzerland, Italy
University Hospital, Lille
INSERM U1189 ONCOTHAI

Recruiting

The IMmunotherapy Pleural 5-ALA PDT (IMPALA)

Malignant Pleural Mesothelioma | Mesotheliomas Pleural

France
Åslaug Helland
Bristol-Myers Squibb; Oslo University Hospital; Ultimovacs ASA

Active, not recruiting

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)

Cancer | Mesothelioma | Mesotheliomas Pleural | Cancer of Lung | Cancer, Lung | Mesothelioma; Pleura | Mesothelioma; Lung

Norway, Denmark, Sweden, Spain, Australia
AGC Biologics S.p.A.

Completed

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (NGR019)

Advanced Malignant Pleural Mesothelioma

Italy, Germany, Russian Federation
Instituto Nacional de Cancerologia de Mexico
National Council of Science and Technology, Mexico

Unknown

Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma

Advanced Malignant Pleural Mesothelioma

Mexico
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Biphasic Mesothelioma | Epithelioid Mesothelioma | Peritoneal Malignant Mesothelioma | Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Pleural Sarcomatoid Mesothelioma | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Biphasic Mesothelioma | Epithelioid Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage I Pleural Malignant Mesothelioma AJCC v7 | Stage IA Pleural Malignant Mesothelioma AJCC v7 | Stage IB Pleural Malignant Mesothelioma AJCC v7 | Stage II Pleural Malignant Mesothelioma AJCC...

United States
MedImmune LLC

Active, not recruiting

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab)

Unresectable Pleural or Peritoneal Malignant Mesothelioma

United States, Italy, Spain, United Kingdom, Belgium, Canada, Poland, France, Korea, Republic of, Hungary, Russian Federation, Germany, Australia, South Africa, Netherlands, Romania, Sweden, Israel, Denmark
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals

Terminated

A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy (DOVE-M)

Advanced Malignant Pleural Mesothelioma | MPM

Canada
ProgenaBiome

Recruiting

A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma

Mesothelioma | Mesotheliomas Pleural | Mesothelioma Peritoneum | Mesothelioma Malignant | Mesothelioma; Lung | Mesothelioma; Liver | Mesothelioma; Omentum

United States
Groupe Français de Pneumo-Cancérologie
Bristol-Myers Squibb

Active, not recruiting

Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE) (MESO-IMMUNE)

Malignant Pleural Mesothelioma | Unresectable Malignant Neoplasm

France
Hutchison Medipharma Limited

Recruiting

HMPL-453 in Advanced Malignant Mesothelioma

Advanced Malignant Mesothelioma

China
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Canada
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Mesothelioma, Malignant | Mesothelioma, Malignant Pleural | Mesothelioma Malignant Advanced

China
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Puerto Rico
Polaris Group

Terminated

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (TRAP)

Glioma | Hepatocellular Carcinoma | Uveal Melanoma | Sarcomatoid Carcinoma | Pleural Mesothelioma Malignant Advanced | Peritoneal Mesothelioma Malignant Advanced | Non-squamous Non-small Cell Lung Carcinoma

United States, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid Neoplasm

United States, Canada
Syndax Pharmaceuticals

Completed

A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors

Solid Tumor | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | Metastatic Tumor

United States
M.D. Anderson Cancer Center

Terminated

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma

United States
Tianjin Medical University Second Hospital

Recruiting

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma, Advanced

China
Genentech, Inc.

Completed

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)

Advanced Unresectable or Metastatic Solid Malignancy

United States
National Cancer Institute (NCI)

Terminated

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Epithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural Mesothelioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Withdrawn

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma
National Cancer Institute (NCI)

Completed

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Localized Malignant Mesothelioma

United States
AstraZeneca

Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

Denmark, Italy, Australia, Korea, Republic of, Belgium, United States, Canada, Japan, United Kingdom, China, Brazil, France, Taiwan, Spain, Norway, Switzerland, Turkey, Poland, Germany, South Africa, Netherlands
M.D. Anderson Cancer Center

Terminated

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
ETOP IBCSG Partners Foundation
Hoffmann-La Roche

Active, not recruiting

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (BEAT-meso)

Pleural Mesothelioma Malignant Advanced

Switzerland, United Kingdom, Belgium, Spain, France, Italy
ETOP IBCSG Partners Foundation
Merck Sharp & Dohme LLC; Frontier Science Foundation, Hellas

Completed

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma (PROMISE-meso)

Pleural Mesothelioma Malignant Advanced

United Kingdom, Switzerland, Spain
European Organisation for Research and Treatment...
ETOP IBCSG Partners Foundation

Completed

SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access (SPECTAlung)

Any Stage of Lung Cancer (Any Histotype) | Any Stage of Malignant Pleural Mesothelioma | Any Stage of Any Thymic Malignancy

Spain, Belgium, Ireland, Slovenia, France, United Kingdom, Poland, Italy, Switzerland

Clinical Trials on Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations